Praxis Precision Medicines reported its small‑molecule ulixacaltamide met primary endpoints across two Phase 3 studies in essential tremor, delivering clinically meaningful functional improvements and maintenance of effect in randomized‑withdrawal designs. The company plans an NDA submission in early 2026 based on the data package and large patient interest reflected in trial enrollment. Markets responded immediately, sending Praxis shares sharply higher and prompting broader attention to T‑type calcium channel inhibition as a therapeutic mechanism in movement disorders. Sponsors emphasized safety profiles and robustness across prespecified secondary endpoints as they finalize regulatory filings.